Appraisal in progress
Indication |
|
| Status: In progress | |
Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Intuniv® must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures. |
|
Medicine details |
|
| Medicine name | guanfacine (Intuniv®) |
| Formulation | 1 mg, 2 mg, 3 mg and 4 mg prolonged-release tablets |
| Reference number | 6440 |
| Indication | As above |
| Company | Takeda UK Limited |
| BNF chapter | Central nervous system |
| Submission type | Limited |
| Status | In progress |
| Scrutiny Panel meeting date | 09/01/2025 |
| LOWMAG meeting date | TBC |
| AWMSG meeting date | TBC |
| Date of issue | TBC |
| Further information The AWMSG Scrutiny Panel considered guanfacine suitable for a limited reassessment. |
|